Medtronic has reported positive data from a trial of its Phased RF Ablation System for persistent atrial fibrillation.

The percutaneous cardiac catheter and generator system delivers customised radiofrequency energy, eliminating or isolating the abnormal electrical impulses in the left atrium that initiate or sustain atrial fibrillation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Data from the Medtronic Tailored Treatment of Permanent Atrial Fibrillation trial showed that 55.8% of ablation management patients experienced an atrial fibrillation and atrial flutter burden reduction of more than 90%, and were free of anti-arrhythmic drug therapy at six months. This was achieved of only 26.4% of patients in the traditional medical management arm.

Patients in the ablation arm received two ablations using the Phased RF Ablation System to achieve treatment success, and were followed at one, three and six months post-treatment, while patients in the medical management arm received anti-arrhythmic drug changes and direct current cardioversions to achieve and maintain sinus rhythm, and were followed at one, three and six months.